Last updated on September 2018

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment


Brief description of study

Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.

Detailed Study Description

This is a Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors with varying degrees of renal impairment. The study is conducted in 2 parts: the Pharmacokinetic Part (Cycle 1) and the Extension Part (Cycles 2 and beyond). Patients may continue to receive treatment with TAS-102 during the study extension part only after completion of the Pharmacokinetic Part.

Clinical Study Identifier: NCT02301117

Find a site near you

Start Over

Phoenix Clinical Site

Phoenix, AZ United States
  Connect »

Duarte Clinical Site

Duarte, CA United States
  Connect »

Santa Monica Clinical Site

Santa Monica, CA United States
  Connect »

Gainesville Clinical Site

Gainesville, FL United States
  Connect »

Baltimore Clinical Site

Baltimore, MD United States
  Connect »

Boston Clinical Site

Boston, MA United States
  Connect »

Cleveland Clinical Site

Cleveland, OH United States
  Connect »

Pittsburgh Clinical Site

Pittsburgh, PA United States
  Connect »

Dallas Clinical Site

Dallas, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.